The verdict
Our read at a glance.
Whether a drug with legitimate antidepressant use abroad is safe to buy over a counter in the United States as a mood or nootropic product.
- The signal
- There are two literatures and they describe the same molecule. The clinical one is real: tianeptine is an established atypical antidepressant with randomized trials in major depression and comparisons across chronic pain and bipolar depression, and a modified-release version has been taken into modern controlled trials. The other literature is toxicological, and it is unambiguous - reviews tracing the path from antidepressant to street drug, and pharmacology papers describing it explicitly as an antidepressant with opioid agonist effects and abuse potential. FDA has warned consumers about products containing it, and poison-centre exposure calls have risen sharply.
- The unknown
- Very little about the pharmacology. The open question is regulatory: how a substance that is an unapproved drug in the United States continues to be sold at retail as a supplement.
- Our read
- The clearest current example of legal availability being mistaken for safety. This is not a supplement with opioid-like side effects; it is a mu-opioid agonist being sold beside the energy drinks. That it is a real medicine somewhere else is precisely what makes the retail version so effective at reassuring people.
The mechanism
How it works.
Tianeptine was originally described as a selective serotonin reuptake enhancer - the opposite of an SSRI - and later work reframed it around glutamatergic signalling and synaptic plasticity in the hippocampus and amygdala, which is the mechanism usually credited for its antidepressant effect at therapeutic doses. What was established more recently is that it is also a full agonist at the mu-opioid receptor, with meaningful potency. At the low doses used clinically that activity is modest and the drug behaves like an atypical antidepressant. At the doses found in retail products, mu-opioid agonism dominates, and the compound then does what mu-opioid agonists do: euphoria, tolerance with repeated use, physical dependence, an opioid withdrawal syndrome on stopping, and respiratory depression in overdose.
Safety & regulatory boundary
The consequential part.
Not approved by FDA for any use and not a lawful dietary supplement ingredient, though it is a licensed medicine in several other countries. It is a full agonist at the mu-opioid receptor, which is the mechanism behind both the euphoria and the dependence, and the doses in retail products are frequently far above any therapeutic range. Documented harms include dependence, an opioid-type withdrawal syndrome, respiratory depression, seizures and death. Several US states have scheduled it independently.
What's next
What we're watching.
FDA enforcement against retail products, state-level scheduling, and the modified-release clinical programme, which is a separate question from the retail products.
Context
Why this is discussed.
It is sold openly as a supplement with names like ZaZa and Neptune's Fix, it produces a genuine mood lift, and its legal availability is read as evidence that it is benign.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE4 · TERMINATED · 2020-10-14
ClinicalTrials.gov · NA · COMPLETED · 2023-06-21
ClinicalTrials.gov · PHASE2 · COMPLETED · 2023-03-02
ClinicalTrials.gov · COMPLETED · 2022-07-04
ClinicalTrials.gov · PHASE2 · RECRUITING · 2023-02-17
ClinicalTrials.gov · NA · UNKNOWN · 2014-12-15
ClinicalTrials.gov · PHASE1 · COMPLETED · 2009-04
ClinicalTrials.gov · PHASE3 · UNKNOWN · 2009-03
Indexed literature (PubMed)12
Alamo C et al. · Rev Psiquiatr Salud Ment (Engl Ed) · 2019
Nishio Y et al. · ACS Chem Neurosci · 2024
Wagner ML et al. · Cureus · 2023
Edinoff AN et al. · Pain Ther · 2023
Wagstaff AJ et al. · CNS Drugs · 2001
Springer J et al. · J Psychoactive Drugs · 2018
Lauhan R et al. · Psychosomatics · 2018
Uzbay TI · Prog Neuropsychopharmacol Biol Psychiatry · 2008
Kishi T et al. · Mol Psychiatry · 2023
Karim A et al. · J Psychiatr Pract · 2020
Smith KE et al. · J Psychoactive Drugs · 2025
Hargett JL et al. · J Addict Nurs · 2023
Keep reading